sponsored
PatientsVille.com Logo

PatientsVille

Olmesar Medical Research Studies

Up-to-date List of Olmesar Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Olmesar Medical Research Studies

Rank Status Study
1 Recruiting Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Condition: Hypertension
Interventions: Drug: LCZ696;   Drug: Olmesartan;   Drug: Placebo of LCZ696;   Drug: Placebo of Olmesartan
Outcome Measures: Change from baseline in 24-hour mean ambulatory systolic blood pressure (maSBP);   Change from baseline in mean 24-hour ambulatory diastolic blood pressure (maDBP);   Change from baseline in mean sitting systolic blood pressure (msSBP);   Change from baseline in mean sitting diastolic blood pressure (msDBP);   Change from baseline in office pulse pressure;   Percentage of patients achieving successful overall blood pressure control;   Number of patients with total adverse events, serious adverse events and death;   Percentage of patients achieving successful mean sitting systolic blood pressure (msSBP) control;   Percentage of patients achieving successful mean sitting diastolic blood pressure (msDBP) control;   Percentage of patients achieving successful mean sitting systolic blood pressure (msSBP) response;   Percentage of patients achieving successful mean sitting diastolic blood pressure (msDBP) response
2 Recruiting Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: LCZ696;   Drug: Olmesartan;   Drug: Placebo of LCZ696;   Drug: Placebo of Olmesartan
Outcome Measures: Change from baseline in mean sitting systolic blood pressure (msSBP) between LCZ696 200 mg versus Olmesartan 20 mg;   Change from baseline in mean sitting systolic blood pressure between LCZ696 400 mg versus Olmesartan 20 mg;   Change from baseline in mean sitting diastolic blood pressure;   Change from baseline in office pulse pressure;   Change from baseline in mean 24-hour ambulatory blood pressure;   Sub-group analysis for change from baseline in mean ambulatory systolic and diastolic blood pressure for nocturnal blood pressure dipper and non-dipper;   Percentage of patients achieving successful blood pressure control;   Number of patients with adverse events, serious adverse events, and death as assessment of safety and tolerability;   Change from baseline in ambulatory pulse pressure;   Percentage of responders
3 Recruiting Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
Condition: Essential Hypertension
Interventions: Drug: CS8635 20/5/12.5mg and placebo;   Drug: Olmetec® Plus 20/12.5mg and placebo
Outcome Measures: The changes of seated diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   The changes of mean seated systolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   The changes of mean seated systolic and diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   Percentage of subjects achieving blood pressure goal of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg;   Percentage of subjects achieving blood pressure goal of the Triple Combinations OM/AML/HCTZ 40/5/12.5mg vs.OM/AML/HCTZ 20/5/12.5mg;   The changes of mean seated systolic and diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 40/5/12.5mg vs.OM/AML/HCTZ 20/5/12.5mg
4 Recruiting Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
Condition: Hypertension
Interventions: Drug: LCZ696;   Drug: Olmesartan;   Drug: LCZ696 matching placebo;   Drug: Olmesartan matching placebo;   Drug: amlodipine;   Drug: hydrochlorothiazide
Outcome Measures: Change from baseline in mean central aortic systolic blood pressure at 12 weeks;   Change from baseline in mean central pulse pressure;   Change from baseline in mean aortic pulse wave velocity;   Change from baseline in mean central aortic systolic blood pressure at 52 weeks;   Change from baseline in mean sitting systolic blood pressure;   Change from baseline in mean sitting diastolic blood pressure;   Change from baseline in mean sitting pulse pressure;   Change from baseline in mean arterial pressure;   Change from baseline in mean 24-hour systolic blood pressure;   Change from baseline in mean 24-hour diastolic blood pressure;   Change from baseline in mean 24-hour ambulatory pulse pressure
5 Recruiting Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
Condition: Hypertension
Intervention: Drug: Amlodipine + Olmesartan medoxomil
Outcome Measures: Number of participants with each Adverse Events being reported;   Efficacy: change from baseline in mean SBP and DBP at week 12 using the LOCF;   Efficacy: change from baseline in mean SBP and DBP at week 4, 8 and 12 without LOCF;   Efficacy: proportion of subjects achieving the JNC VII recommended BP goal (<140/90 mmHg; <130/80 mmHg for subjects with diabetes) at week 12 with LOCF
6 Unknown  Olmesartan on Ambulatory Blood Pressure Change
Condition: Hypertension
Intervention: Drug: Olmesartan
Outcome Measures: The primary objective is the change in the 24-hour mean systolic blood pressure from baseline to the day after post-treatment week-12 visit according to the ambulatory blood pressure monitoring.;   Change in the 24-hour mean diastolic blood pressure from baseline to the day after post-treatment week-12 visit
7 Recruiting Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Conditions: Hypertension;   Chronic Kidney Disease;   Microalbuminuria
Intervention: Behavioral: Intensive education for low salt diet
Outcome Measures: Change in albuminuria as a spot urine albumin to creatinine ratio by intensive education of low salt diet during taking Olmesartan;   The change of hemoglobin after prescription of Olmesartan is proportional to the change of albuminuria;   Change of sodium excretion rate in 24 hour-urine collection by intensive education for low salt diet;   Intensive education for low salt diet induces the significant decrease of blood pressure in Intervention group compared to control group.
8 Recruiting A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
Condition: Hypertension
Interventions: Drug: LCZ696;   Drug: Olmesartan;   Other: placebo to LCZ696;   Other: placebo to Olmesartan
Outcome Measures: Change from baseline in ascending aorta distensibility at 12 weeks;   Change from baseline in proximal descending aorta distensibility at 12 weeks;   Change from baseline in distal descending aorta distensibility at 12 weeks;   Change from baseline in local aortic strain at 12 weeks;   Change from baseline in regional aortic pulse wave velocity at 12 weeks;   Change from baseline in Central blood pressure at 12 weeks;   Change from baseline in augmentation pressure at 12 weeks;   Change from baseline in augmentation index at 12 weeks;   Change from baseline in pulse wave velocity at 12 weeks;   Number of patients with reported adverse events, serious adverse events and death
9 Not yet recruiting Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult Volunteers
Condition: Healthy
Interventions: Drug: Sevikar(amlodipne/Olmesartan);   Drug: crestor(Rosuvastatin)
Outcome Measures: AUCtau;   Css,max;   Tss,max;   Css,min
10 Recruiting Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Cardiovascular Risk Assessment
Conditions: Essential Hypertension;   Cardiovascular Disease;   Stroke;   Chronic Kidney Disease
Interventions: Drug: Any antihypertensive medication alone or in combination;   Device: Ambulatory blood pressure monitoring
Outcome Measures: To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.;   To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.;   To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.;   To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.;   To evaluate, for all previous objectives, potential differences between men and women.;   To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment.
11 Recruiting Recurrent Stroke Prevention Clinical Outcome Study
Conditions: Hypertension;   Stroke;   Blood Pressure
Intervention: Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
Outcome Measures: the prevention of recurrent stroke.;   The incidence of events other than stroke
12 Not yet recruiting Angiotensin II Antagonist in Severe Sepsis
Condition: Severe Sepsis
Intervention: Drug: Irbesartan
Outcome Measures: mortality;   Incidence of altered organ function in sepsis patients measured by SOFA score (Sequential Organ Failure Assessment score)
13 Recruiting Resistant Arterial Hypertension Cohort Study
Conditions: Hypertension;   Essential Hypertension;   Resistant Hypertension
Interventions: Drug: chlorthalidone;   Behavioral: motivational intervention for non-compliant individuals;   Drug: standardized anti-hypertensive treatment
Outcome Measures: blood pressure control;   cardiovascular morbidity and mortality
14 Recruiting Medication Adherence and "True" Resistance in Patients With Resistant Hypertension
Conditions: Hypertensive Disease;   Hypertension, Resistant to Conventional Therapy
Intervention:
Outcome Measures: Estimation of the proportion of patients with "true" resistance among patients referred to the Medical Outpatient Department of the Charité - Universitätsmedizin Berlin with the diagnosis "resistant hypertension";   Assessment of all costs of both treatments within one year.;   Analysis of medication adherence at baseline, after fixed-dose triple combination treatment and in the end of the study via therapeutic drug monitoring, and correlation of these results with the questionnaire findings.;   Explorative evaluation of the efficacy of renal sympathetic denervation compared to an intensified drug treatment based on ambulatory blood pressure and ambulatory blood pressure measurement over 24 hours.;   Assessment of adverse events in order to evaluate the safety of both treatments.
15 Recruiting Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics
Condition: Hypertension
Intervention: Other: Sevoflurane/oxygen/air/nitrous oxide
Outcome Measures: Systemic Vascular Resistance Index (SVRI);   Heart Rate;   Systolic Blood Pressure;   Diastolic Blood Pressure;   Central Venous Pressure;   Cardiac Output (CO);   Cardiac Index (CI);   Stroke Volume Varriation;   Systemic Vascular Resistance

These studies may lead to new treatments and are adding insight into Olmesar etiology and treatment.

A major focus of Olmesar research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Olmesar